Azimuth Collective is a proudly veteran-owned brand in the Canadian cannabis market.

Arron has been working with market leaders in the Canadian medical cannabis space providing strategic guidance since 2016. Arron will lead the team at Azimuth Collective to prof itability as a brand through a strategy focused on our core consumers and what value we offer them through our line of medical cannabis products Arron currently holds a position on the advisory board for the Chronic Pain Center of Excellence, as well as an ambassador position with Wounded Warriors Canada.

Psychedelics, entheogens, entactogens and dissociative anaesthetics, and cannabis are the sole focus of David’s intellectual property, regulatory and commercial practice. Driven by a strong personal commitment to responsible and effective access to psychedelics for improving, maintaining, and promoting mental health, David supports pro bono initiatives by nonprofit organizations to facilitate and expand access to psilocybin, MDMA and other psychedelics for Canadians, both within and separate from Canada’s prescription drug system under the Food and Drugs Act. David holds a PhD in biochemistry. His graduate-level education in structural biochemistry, synthetic organic chemistry, plant biochemistry, and natural products chemistry provides a strong technical background for advising clients working with psychedelics and clients working in Canada’s cannabis industry in relation to both intellectual property and regulatory law.

Amy is a former marketing executive turned investor, advisor and consultant. Amy played a pivotal role from 2015 through 2020 in building, launching and commercializing Canopy Growth’s suite of 20+ medical and adult-use cannabis brands, as Vice President of Brand Marketing + Innovation.

Founder and CEO of Token Naturals, a rapidly-growing production development company in the Canadian cannabis industry. Keenan leads a team that is building a comprehensive facility in central Edmonton and executing a series-A fundrise in the lead up to producing a range of extracted cannabis products. Keenan currently acts as a mentor through StartUp Edmonton’s Foundations for Black Founders.

Victoria is an award-winning journalist, communications strategist and public relations specialist. Currently serving in a leadership capacity for global psychedelics brands and having served Canada’s largest founding licensed cannabis producers, she brings deep passion for cognitive liberty to her work.

Michael represents issuers and financers in public and private debt and equity financings, mergers & acquisitions, and corporate governance matters. Michael leads BLG deal teams on corporate finance, governance, disclosure, transaction structuring, public listing, and M&A matters in the energy, technology, psychedelics, cannabis and renewable energy industries. Michael is a board member and committee chair for various companies.

Khurshid Khoja is Founder of Greenbridge Corporate Counsel, a minority-owned business law firm founded in 2012, representing clientele in California, Oregon, Washington and Hawaii from across numerous sectors in the legal cannabis industry. Khurshid is a business lawyer with over fifteen years of experience, and has been advising clients in the cannabis industry since 2011 on a broad array of regulatory, commercial and transactional matters.

Matt O’Brien is an education consultant, and formerly the founder of Four PM – a daily cannabis publication (acquired by WorkWeek) that provided 20,000+ cannabis professionals across North America with the information they need to stay up to date on everything that is happening inside the cannabis industry.

Dr Lekos is a green chemist and bioengineer focused on utilizing plants and microorganisms to make medicine. For over 20 years he has developed novel value added agricultural products for both industry and academia. He has been a professor at Western Washington University and Washington State University. He has worked on several clinical studies that utilize plant based medicine for PTSD, nausea induced from chemotherapy, epilepsy and brain tumors. He also serves on several boards and as a product development chemist for multiple pharmaceutical and cannabis companies.